| abstract |
The present invention relates to the use of a compound of formula I in the manufacture of a medicament for the treatment of ophthalmic disorders, skin disorders, conditions associated with damaging effects from vesiculating agents, and autoimmune, inflammatory, neurological and cardiovascular diseases due to the use of primary amines for the removal of toxic aldehydes such as MDA and HNE Prevention, and / or reduction of risk of a disease, disorder, or condition in which aldehyde toxicity is associated with an onset. |